TsuyukiRTHouleSKCharroisTL, et al. Randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: the Alberta Clinical Trial in Optimizing Hypertension (RxACTION). Circulation2015;132(2):93-100.
2.
Al HamarnehYNCharroisTLewanczukRTsuyukiRT.Pharmacist intervention for glycaemic control in the community (the RxING study). BMJ Open2013;3(9):e003154.
3.
TsuyukiRTRosenthalMPearsonGJ.A randomized trial of a community-based approach to dyslipidemia management: pharmacist prescribing to achieve cholesterol targets (RxACT Study). Can Pharm J (Ott)2016;149(5):283-92.
4.
TsuyukiRTAl HamarnehYNJonesCAHemmelgarnBR.The effectiveness of pharmacist interventions on cardiovascular risk: the multicenter randomized controlled RxEACH trial. J Am Coll Cardiol2016;67(24):2846-54.
5.
BeahmNPSmythDJTsuyukiRT.Outcomes of Urinary Tract Infection Management by Pharmacists (RxOUTMAP): a study of pharmacist prescribing and care in patients with uncomplicated urinary tract infections in the community. Can Pharm J (Ott)2018;151(5):305-14.
6.
MarraCJohnstonKSantschiVTsuyukiRT.Cost-effectiveness of pharmacist care for managing hypertension in Canada. Can Pharm J (Ott)2017;150(3):184-97.
7.
SanyalCHusereauDRBeahmNPSmythDTsuyukiRT.Cost-effectiveness and budget impact of the management of uncomplicated urinary tract infection by community pharmacists. BMC Health Serv Res2019;19(1): 499.
8.
Al HarmarnehYNLambSDonaldM, et al. Pharmacist prescribing and care improves cardiovascular risk, but what do patients think? A substudy of the RxEACH study. Can Pharm J (Ott)2018;151(4):223-7.
